![]() Express Diagnostics Int'l Express Diagnostics Int'l is a company that manufactures and distributes DrugCheck, onsite urine and saliva screening devices for the detection of drugs of abuse. | ![]() SiteOne Therapeutics SiteOne Therapeutics is a company that develops therapeutics for the treatment of hypersensitivity disorders. | SPARK Neuro SPARK Neuro is a neuroscience company that provides drug development and clinical care solutions. | ![]() Inflazome Inflazome engages in developing orally available drugs to address clinical unmet needs in inflammatory diseases by targeting the inflammasome. | ||
Founding Date | Founding Date 2004 | Founding Date 2014 | Founding Date 2016 | Founding Date 2014 | Founding Date 2016 |
Type | Type Private | Type Private | Type Private | Type Private | Type Subsidiary |
Tags | |||||
Locations | Locations Blue Earth, US HQ | Locations San Francisco, US HQ Bozeman, US | Locations Santa Monica, US HQ | Locations Seattle, US HQ | Locations Dublin 2, IE HQ Brisbane City, AU Cambridge, GB |
Employees | Employees 17 | Employees 2216% increase | Employees 234% decrease | Employees 3 | Employees 156% decrease |
Valuation ($) | Valuation ($) N/A | Valuation ($) 75 m | Valuation ($) 53.5 m | Valuation ($) N/A | Valuation ($) N/A |
Funding | |||||
Latest funding round | Latest funding round N/A | Latest funding round $ 15m (over 9 years ago) | Latest funding round $ 13.5m (almost 8 years ago) | Latest funding round N/A | Latest funding round N/A |
Total funding raised | Total funding raised N/A | Total funding raised $ 17.8m | Total funding raised $ 13.5m | Total funding raised N/A | Total funding raised $ 17m |

SiteOne Therapeutics is a company that develops therapeutics for the treatment of hypersensitivity disorders.
View companySPARK Neuro is a neuroscience company that provides drug development and clinical care solutions.
View company
PreCyte is a healthcare company that provides diagnostic solutions.
View company
Inflazome engages in developing orally available drugs to address clinical unmet needs in inflammatory diseases by targeting the inflammasome.
View company